{
    "ticker": "DKILY",
    "name": "Daiichi Sankyo Company, Limited",
    "description": "Daiichi Sankyo Company, Limited is a global pharmaceutical company based in Japan, known for its innovative medicines and commitment to healthcare. Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Limited, Daiichi Sankyo focuses on the research, development, manufacturing, and marketing of pharmaceutical products. The company has a diverse portfolio that includes treatments for cardiovascular diseases, oncology, and infectious diseases. Notably, it is recognized for its oncology drug, Enhertu (fam-trastuzumab deruxtecan-nxki), which has shown promising results in treating certain types of breast and gastric cancers. With a strong emphasis on research and development, Daiichi Sankyo invests heavily in new therapies and technologies, aiming to address unmet medical needs and improve patient outcomes globally. The company operates with a vision to become a 'Global Pharma Innovator' by leveraging its scientific expertise and technological capabilities. Through strategic partnerships and collaborations, Daiichi Sankyo enhances its ability to bring innovative solutions to market, while maintaining a strong commitment to sustainability and corporate social responsibility.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Tokyo, Japan",
    "founded": "2005",
    "website": "https://www.daiichisankyo.com",
    "ceo": "Seigo Kikuchi",
    "social_media": {
        "twitter": "https://twitter.com/daiichisankyo",
        "linkedin": "https://www.linkedin.com/company/daiichi-sankyo/"
    },
    "investor_relations": "https://www.daiichisankyo.com/ir/index.html",
    "key_executives": [
        {
            "name": "Seigo Kikuchi",
            "position": "CEO"
        },
        {
            "name": "Fumio Matsuda",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "Enhertu",
                "Talquetamab"
            ]
        },
        {
            "category": "Cardiovascular",
            "products": [
                "Olmesartan",
                "Perindopril"
            ]
        }
    ],
    "seo": {
        "meta_title": "Daiichi Sankyo Company, Limited | Global Pharmaceutical Innovator",
        "meta_description": "Explore Daiichi Sankyo Company, Limited, a global leader in pharmaceuticals focused on innovative treatments for cancer, cardiovascular diseases, and more.",
        "keywords": [
            "Daiichi Sankyo",
            "Pharmaceuticals",
            "Oncology",
            "Cardiovascular",
            "Innovative Medicines",
            "Enhertu"
        ]
    },
    "faq": [
        {
            "question": "What is Daiichi Sankyo known for?",
            "answer": "Daiichi Sankyo is known for its innovative pharmaceutical products, particularly in oncology and cardiovascular diseases."
        },
        {
            "question": "Who is the CEO of Daiichi Sankyo?",
            "answer": "Seigo Kikuchi is the CEO of Daiichi Sankyo Company, Limited."
        },
        {
            "question": "Where is Daiichi Sankyo headquartered?",
            "answer": "Daiichi Sankyo is headquartered in Tokyo, Japan."
        },
        {
            "question": "What are Daiichi Sankyo's main products?",
            "answer": "Daiichi Sankyo's main products include Enhertu, Olmesartan, and Perindopril."
        },
        {
            "question": "When was Daiichi Sankyo founded?",
            "answer": "Daiichi Sankyo was founded in 2005."
        }
    ],
    "competitors": [
        "PFE",
        "ABT",
        "NVS",
        "MRK"
    ],
    "related_stocks": [
        "JNJ",
        "GSK",
        "BMY",
        "SNY"
    ]
}